Pfizer (PFE) Free Cash Flow (2009 - 2026)

Pfizer (PFE) has 18 years of Free Cash Flow data on file, last reported at $2.2 billion in Q1 2026.

• Free Cash Flow for Q1 2026 came in at $2.2 billion, up 23.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 billion (up 180.23% YoY), and the FY2025 annual result was $9.1 billion, down 7.73% from the prior year.
• Free Cash Flow retreated to $2.2 billion in Q1 2026 per PFE's latest filing, from $4.5 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $18.5 billion in Q4 2022 and troughed at -$2.4 billion in Q2 2024.
• A 5-year average of $3.3 billion and a median of $2.6 billion in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow sank 128.6% in 2023, then surged 428.77% in 2024.
• A 5-year view of Free Cash Flow shows it stood at $18.5 billion in 2022, then tumbled by 77.26% to $4.2 billion in 2023, then dropped by 3.93% to $4.0 billion in 2024, then climbed by 11.71% to $4.5 billion in 2025, then slumped by 51.61% to $2.2 billion in 2026.
• Business Quant data shows PFE's Free Cash Flow at $2.2 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.